Patents by Inventor Roman Thomas
Roman Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240263678Abstract: The present invention provides a method and apparatus for braking mecanum or omnidirectional wheels, by applying force to the rollers of a mecanum or omnidirectional wheel to prevent them from rolling when in contact with the ground or the floor. In some embodiments, it engages the rollers with teeth, rods, or wedges to generate friction and prevent them from rotating. The teeth, rods, or wedges rotate with the mecanum or omnidirectional wheel on the same axle, so the force can be applied and the rollers braked whether the wheel is rotating or not. In some embodiments, the force is applied using a servo or motor to push a thrust bearing, which then engages the rollers. In some embodiments, the servo or motor applies force using one or more gear racks, levers, cam wheels, or mechanical linkages.Type: ApplicationFiled: January 26, 2024Publication date: August 8, 2024Inventors: Jason Andrew Voth, Joshua David Petry, Noah Bradley Praske, Emma Ruth Praske, Seth Thomas Dodds, Roman Martin Lefler, Eric Jon Voth
-
Publication number: 20240256850Abstract: A trained neural network is partitioned into a client-side portion and a server-side portion, the client-side portion comprising a first set of layers of the trained neural network, the server-side portion comprising a second set of layers of the trained neural network, the trained neural network trained using a first set of training data. From a homomorphically encrypted intermediate result input to the server-side portion, a homomorphically encrypted output of the trained neural network is computed, the homomorphically encrypted intermediate result comprising a homomorphically encrypted output computed by the client-side portion.Type: ApplicationFiled: January 30, 2023Publication date: August 1, 2024Applicant: International Business Machines CorporationInventors: Omri Soceanu, Nir Drucker, Subhankar Pal, Roman Vaculin, Kanthi Sarpatwar, Alper Buyuktosunoglu, Pradip Bose, Hayim Shaul, Ehud Aharoni, James Thomas Rayfield
-
Patent number: 12041157Abstract: Privacy-preserving homomorphic inferencing utilizes batch processing on encrypted data records. Each data record has a private data portion of interest against which the inferencing is carried out. Batch processing is enabled with respect to a set of encrypted data records by techniques that ensure that each encrypted data record has its associated private data portion in a unique location relative to the other data records. The set of encrypted data records are then summed to generate a single encrypted data record against which the inferencing is done. In a first embodiment, the private data portions of interest are selectively and uniquely positioned at runtime (when the inferencing is being applied). In a second embodiment, the private data portions of interest are initially positioned with the data-at-rest, preferably in an off-line process; thereafter, at runtime individual encrypted data records are processed as necessary to adjust the private data portions to unique positions prior to batching.Type: GrantFiled: May 10, 2021Date of Patent: July 16, 2024Assignee: International Business Machines CorporationInventors: Kanthi Sarpatwar, Roman Vaculin, Ehud Aharoni, James Thomas Rayfield, Omri Soceanu
-
Patent number: 10208354Abstract: The present invention relates to novel fusion genes comprising NRG1 and a further fusion partner, like CD74. The present invention provides for the use of these fusion genes in diagnosis as well as in medical intervention in cancer.Type: GrantFiled: August 7, 2014Date of Patent: February 19, 2019Assignee: Universität zu KölnInventors: Lynnette Fernandez-Cuesta, Julie George, Dennis Plenker, Roman Thomas
-
Patent number: 10131177Abstract: A barrier film, a document including a barrier coating, and a method for producing a document are described. A document includes a substrate, printed data on a surface of the substrate, and a barrier coating. The barrier coating is disposed between a portion of the printed data and a portion of an adhesive. The portion of the adhesive is disposed between a portion of a protective layer and a portion of the substrate.Type: GrantFiled: February 7, 2014Date of Patent: November 20, 2018Assignee: ENTRUST DATACARD CORPORATIONInventors: Roman Thomas Knipp, Peter Daniel Schmidt
-
Publication number: 20170228632Abstract: Systems and methods wherein one or more processing operations on an identification document occur after a radiation curable material is applied to a surface of the identification document but before the radiation curable material is fully cured. The one or more processing operations can occur before any curing of the radiation curable material takes place. Alternatively, the one or more processing operations can occur after the radiation curable material has been partially cured, and before the radiation curable material is fully or completely cured.Type: ApplicationFiled: February 3, 2017Publication date: August 10, 2017Inventors: Roman Thomas KNIPP, Pauline UKPABI, Utpal R. VAIDYA, Thomas J. WAGENER, Brian BEECH
-
Publication number: 20160312288Abstract: The present invention relates to novel fusion genes comprising NRG1 and a further fusion partner, like CD74. The present invention provides for the use of these fusion genes in diagnosis as well as in medical intervention in cancer.Type: ApplicationFiled: August 7, 2014Publication date: October 27, 2016Applicant: Universität zu KölnInventors: Lynnette FERNANDEZ-CUESTA, Julie GEORGE, Dennis PLENKER, Roman THOMAS
-
Publication number: 20150329537Abstract: The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.Type: ApplicationFiled: August 22, 2012Publication date: November 19, 2015Applicants: LEADDISCOVERY CENTER GMBH, MAX-PLANCK GESELLSCHAFTZUR FORDERUNG DER WIS SENSCHAFTEN E.VInventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
-
Publication number: 20150224810Abstract: A barrier film, a document including a barrier coating, and a method for producing a document are described. A document includes a substrate, printed data on a surface of the substrate, and a barrier coating. The barrier coating is disposed between a portion of the printed data and a portion of an adhesive. The portion of the adhesive is disposed between a portion of a protective layer and a portion of the substrate.Type: ApplicationFiled: February 7, 2014Publication date: August 13, 2015Applicant: DATACARD CORPORATIONInventors: Roman Thomas KNIPP, Peter Daniel SCHMIDT
-
Publication number: 20140303167Abstract: The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.Type: ApplicationFiled: August 22, 2012Publication date: October 9, 2014Applicant: LEAD DISCOVERY CENTER GMBHInventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
-
Publication number: 20140287454Abstract: The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to a selective CDK9 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with a selective CDK9 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to a selective CDK9 inhibitor, whereby the patient is suspected to suffer from NUT midline carcinoma (NMC). The present invention also relates to a method of monitoring or predicting the efficacy of a treatment of NUT midline carcinoma (NMC), wherein treatment with a selective CDK9 inhibitor is in particular envisaged. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one rearrangement in the NUT gene for screening and/or validation of a medicament for the treatment NUT midline carcinoma (NMC) is described.Type: ApplicationFiled: August 22, 2012Publication date: September 25, 2014Applicants: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LEAD DISCOVERY CENTER GmbHInventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
-
Publication number: 20130023420Abstract: The present invention relates to a combination of cell lines as well as a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to an HSP90 inhibitor anti-tumor agent. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell or collection of cells or cell lines to treatment with a drug such as an HSP90 inhibitor anti-tumor agent is described herein.Type: ApplicationFiled: February 14, 2012Publication date: January 24, 2013Inventors: Roman Thomas, Kathrin Maring, Thomas Zander, Peter Frommolt, Kwok-kin Wong
-
Publication number: 20110319415Abstract: The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to an HSP90 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with an HSP90 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to an HSP90 inhibitor and uses of an oligo- or polynucleotide capable of detecting (an) activating mutation(s) in the KRAS gene are provided. The present invention also relates to a method of monitoring the efficacy of a treatment of a cancer characterized by the presence of at least one activating mutation in the KRAS gene, and. optionally, in the EGFR gene and/or the BRAF gene. In addition, a method of predicting the efficacy of a cancer treatment is described, in particular in a cancer that is characterized by the presence of at least one activating mutation in the KRAS gene. and.Type: ApplicationFiled: August 17, 2009Publication date: December 29, 2011Applicants: Universit+e,uml a+ee t zu K+e,uml o+ee ln, Max-Planck-Gesellschaft zur F+e,uml o+ee rderung der WissensInventors: Roman Thomas, Kathrin Maring, Thomas Zander, Peter Frommolt, Kwok-kin Wong
-
Patent number: 6964530Abstract: A system and method are provided for correcting a hang condition caused by an unanticipated exception during a printing process. The method may include providing a set of predetermined rules according to which the print process modules interact to control the printing process. The method further may include monitoring, from a self-correcting module, a state of each of a plurality of the print process modules. The method may also include determining that the printing device is hung during a printing process, based on at least one predetermined rule and the state of at least one print process module, and setting the state of at least one print process module to a default condition.Type: GrantFiled: January 23, 2004Date of Patent: November 15, 2005Assignee: Hewlett-Packard Development Company, L.P.Inventors: Nataraj Kumar Gobbak, Jeetendra Kumar, Roman Thomas Wachter